Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2007-08-22 Board/Management Inform…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT Appoints David Brookes as Independent Director 2 pages ?Kb
Board/Management Information Classification · 100% confidence The document is an announcement from Living Cell Technologies Limited about the appointment of a new independent director to the company's board. It discusses the replacement of a board member and highlights the new director's qualifications and expected contributions. There is no financial data, no mention of a report or financial results, and the content focuses solely on management/board changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is 4093 characters, which is consistent with a typical announcement rather than a full report.
2007-08-22 English
Initial Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares held directly and indirectly, and interests in contracts. This type of document is a report of personal share transactions or holdings by company directors. It is not an annual report, earnings release, or any other financial report. The document length is short and focused solely on director share interests, matching the definition of Director's Dealing filings.
2007-08-22 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities held by a director, including the number of shares before and after the change, the nature of the transaction (on-market trade), and dates. This is a clear report of personal share transactions by a company director. The document length is 3467 characters, which is typical for such notices. There is no indication that this is a full financial report, audit, or other type of filing. Therefore, the document fits the definition of Director's Dealing (DIRS).
2007-08-02 English
Journal Endorses Durability of LCT Biocapsule 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a press release dated 1 August 2007 from Living Cell Technologies Limited announcing the publication of a scientific journal article endorsing their cell therapy technology. It discusses the scientific study results, the technology's durability, and future clinical trials. There are no financial statements, regulatory filings, or management discussions of financial results. The content is primarily a corporate announcement about scientific validation and product development progress, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation, call transcript, or governance-related document. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2007-07-31 English
Appendix 4C 7 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Cash Flow Report Period Ended 30 June 2007' and is an ASX announcement dated 31 July 2007. It contains detailed financial data including cash flow statements, operating cash flows, investing and financing activities, and reconciliation of cash. The document is approximately 13,881 characters long, indicating it is a substantive report rather than a brief announcement. The presence of detailed financial tables and notes aligns with the characteristics of an Interim / Quarterly Report. The document is not merely an announcement of a report or a certification, but contains actual financial data and analysis for a quarter. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2007
2007-07-30 English
LCT Increases US Investment Support through ADR Program 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a press release dated July 18, 2007, announcing the establishment of a Level 1 American Depositary Receipt (ADR) program for Living Cell Technologies Limited. It discusses the ADR program details, its benefits for US investors, and the company's strategic intentions. There are no financial statements, detailed financial performance data, or regulatory filings such as 10-K or interim reports included. The document is an announcement about a capital market activity related to financing and investor relations, specifically about the ADR program which facilitates trading and investment. This fits the category of Capital/Financing Update (CAP). The document length is 7322 characters, which is sufficient for a detailed announcement but does not contain financial reports or earnings data. Therefore, the correct classification is CAP with high confidence.
2007-07-17 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.